Third Amendment to Second Amended and Restated Investor Rights Agreement by and among Immunicon Corporation and Investors

Summary

This amendment updates the existing Investor Rights Agreement between Immunicon Corporation and its investors. It revises certain terms related to the issuance of company stock, including exceptions to investor rights and conditions for a public offering to qualify as a "Qualified IPO." The amendment reflects changes due to a recent reverse stock split and sets new thresholds for public offerings. All other terms of the original agreement remain in effect. The amendment is effective as of March 15, 2004, and is signed by Immunicon and multiple investor entities.

EX-10.54 5 a2131230zex-10_54.htm EXHIBIT 10.54
QuickLinks -- Click here to rapidly navigate through this document


Exhibit 10.54


THIRD AMENDMENT TO
SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT

        THIS THIRD AMENDMENT TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this "Amendment") is made and entered into as of March 15, 2004, by and among Immunicon Corporation, a Delaware corporation (the "Company"), and certain entities and persons that are parties to that certain Second Amended and Restated Investor Rights Agreement, dated as of December 13, 2001, by and among the Company and the signatories thereto, as amended on March 6, 2002 and as further amended on June 30, 2003 (the "Agreement"). Capitalized terms used herein but not defined shall have the meanings given to such terms in the Agreement.

        WHEREAS, the parties wish to amend the Agreement to effectuate the changes set forth herein.

        NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

            1. Section 3.1(g) of the Agreement is hereby amended to read in its entirety as follows (with the numbers below giving effect to the Company's March 2004 two-for-three reverse stock split):

        "(g) The rights of the Investors under this Section 3 shall not apply to:

        (1)
        Common Stock issued as a stock dividend to holders of Common Stock or upon any subdivision or combination of Common Stock;

        (2)
        Common Stock issued upon conversion of outstanding Stock;

        (3)
        Common Stock or options therefor (including options for Common Stock currently outstanding) issued or issuable to officers, directors, consultants and employees of the Company or any subsidiary pursuant to the Company's stock purchase or option plans in place on the date hereof and in an aggregate amount not to exceed 2,766,667 shares of Common Stock (as adjusted for stock splits, stock dividends, recapitalizations and similar events);

        (4)
        Common Stock offered by the Company in an underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale of Common Stock for the account of the Company to the public;

        (5)
        capital stock issued in connection with an acquisition approved by all of the directors elected by holders of the Stock of the assets or stock of another company so long as no beneficial holder of the acquired entity is, at the time of acquisition, a stockholder, officer or director of the Company or any of its subsidiaries or an affiliate of any such person;

        (6)
        Common Stock, in a number of shares not to exceed an aggregate of 456,667 shares (as adjusted for stock splits, stock dividends, recapitalizations and similar events), issued or issuable in connection with transactions that are primarily for purposes other than raising equity financing approved by all of the non-employee members of the Board of Directors primarily for the purpose of (i) joint ventures, technology licensing or research and development activities, (ii) distribution or manufacture of the corporation's products or services or (iii) any other transactions involving corporate partners; and

        (7)
        Common Stock, in a number of shares not to exceed an aggregate of 456,667 shares (as adjusted for stock splits, stock dividends, recapitalizations and similar events), issued or issuable to equipment lessors, financial institutions or similar entities in transactions approved by all of the non-employee members of the Board of Directors that are primarily for purposes other than raising equity financing; and

        (8)
        Common Stock issued or issuable in connection with a Qualified IPO (as defined below)."

            2. Section 3.2(b) of the Agreement is hereby amended to read in its entirety as follows (with the numbers below giving effect to the Company's March 2004 two-for-three reverse stock split):

        "(b) Upon the closing of the Company's first public offering of Common Stock which meets all of the following requirements: (a) proceeds (net of underwriting discounts and commissions) to the Company of at least $30,000,000 and (b) a price per share of (x) at least $9.00 if such public offering is consummated on or prior to June 30, 2004, or (y) at least $12.00 if such public offering is consummated after June 30, 2004 (in each case as adjusted for stock splits, stock dividends, recapitalizations and similar events) (clauses (a) and (b) shall be referred to herein as a "Qualified IPO")."

            3. As amended hereby, the Agreement is ratified and confirmed in all respects.

[Signature Pages Follow]

2


        IN WITNESS WHEREOF, this Third Amendment to Second Amended and Restated Investor Rights Agreement has been executed as of the date first above written.

    IMMUNICON CORPORATION

 

 

By:

/s/  EDWARD L. ERICKSON      
Edward L. Erickson, Chief Executive Officer

 

 

INVESTORS:

Burrill Biotechnology Capital Fund, L.P.

By: Burrill & Company LLC, its general partner

 

 

By:

/s/  G. STEVEN BURRILL      
G. Steven Burrill, Managing Member

 

 

Burrill Life Sciences Capital Fund, L.P.

By: Burrill & Company LLC, its general partner

 

 

By:

/s/  G. STEVEN BURRILL      
G. Steven Burrill, Managing Member

 

 

Wheatley Partners III, L.P.

By: Wheatley Partners III LLC, its general partner

 

 

By:

/s/  BARRY RUBENSTEIN      
Name: Barry Rubenstein
Title: CEO

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

3


    Wheatley Associates III, L.P.

By: Wheatley Partners III, LLC, its general partner

 

 

By:

/s/  BARRY RUBENSTEIN      
Name: Barry Rubenstein
Title: CEO

 

 

Wheatley Foreign Partners, L.P.

By: Wheatley Partners III, LLC its general partner

 

 

By:

/s/  BARRY RUBENSTEIN      
Name: Barry Rubenstein
Title: CEO

 

 

Wheatley MedTech Partners, L.P.

By: Wheatley MedTech Partners, LLC, its general partner

 

 

By:

/s/  BARRY RUBENSTEIN      
Name: Barry Rubenstein
Title: CEO

 

 

LHC Corporation

 

 

By:

/s/  BRIAN J. GEIGER      
Name: Brian J. Geiger
Title: Executive Vice President

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

4



 

 

MDS Life Sciences Technology Fund Limited Partnership

 

 

By:

MDS Life Sciences Technology Fund (GP) Inc., its general partner

 

 

By:

/s/  GRAYSANNE BEDELL      
Name: Graysanne Bedell
Title: Assistant Secretary

 

 

By:

/s/  GREG GUBITZ      
Name: Greg Gubitz
Title: Vice President

 

 

MDS Life Sciences Technology Fund USA, L.P.
    By: MDS Capital USA (GP) Inc., its general partner

 

 

By:

/s/  THOMAS E. WILLETT      
Name: Thomas E. Willett
Title: Director

 

 

MDS Life Sciences Technology Barbados
Investment Trust

 

 

By:


Name:
Title:

 

 

SC Biotechnology Development Fund LP
    By: SC (GP) Inc.

 

 

By:

/s/  ALAN WALMSLEY      
Name: Alan Walmsley

 

 

By:

/s/  ALAN MILGATE      
Name: Alan Milgate

 

 

 

Title: For and On Behalf of Cardinal Investments Limited, Director of SC (GP) Inc., General Partner of SC Biotechnology Development Fund, L.P.

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

5



 

 

TL Ventures III L.P.

By: TL Ventures III Management L.P., its general partner

By: TL Venture III LLC, its general partner

 

 

By:

/s/  PAMELA A. STRISOFSKY      
Name: Pamela A. Strisofsky
Title: Chief Financial Officer

 

 

TL Ventures III Offshore L.P.

By: TL Ventures III Offshore Partners L.P., its general partner

By: TL Ventures III Offshore Ltd., its general partner

 

 

By:

/s/  PAMELA A. STRISOFSKY      
Name: Pamela A. Strisofsky
Title: Chief Financial Officer

 

 

TL Ventures III Interfund L.P.

By: TL Ventures III LLC, its general partner

 

 

By:

/s/  PAMELA A. STRISOFSKY      
Name: Pamela A. Strisofsky
Title: Chief Financial Officer

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

6



 

 

Canaan Equity, L.P.

By: Canaan Equity Partners, L.L.C.

 

 

By:

/s/  GUY M. RUSSO      
Name: Guy M. Russo
Title: Member/Manager

 

 

Canaan Equity II L.P.

By: Canaan Equity Partners II LLC

 

 

By:

/s/  GUY M. RUSSO      
Name: Guy M. Russo
Title: Member/Manager

 

 

Canaan Equity II L.P. (QP)

By: Canaan Equity Partners II LLC

 

 

By:

/s/  GUY M. RUSSO      
Name: Guy M. Russo
Title: Member/Manager

 

 

Canaan Equity II Entrepreneurs LLC

By: Canaan Equity Partners II LLC

 

 

By:

/s/  GUY M. RUSSO      
Name: Guy M. Russo
Title: Member/Manager

 

 

By:

/s/  SETH A. RUDNICK      
Seth A. Rudnick, M.D.

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

7



 

 

MedCapital Investments, LLC

By: MedCapital, LLC

 

 

By:


Jan Rock, Administrative Member

 

 

Foundation Medical Partners, L.P.

By: Foundation Medical Managers, LLC

 

 

By:

/s/  JONATHAN COOL      
Jonathan Cool, Manager

 

 

Anthem Capital, L.P.

By: Anthem Capital Partners, L.P., its general partner

By: Anthem Capital Partners, Inc., its general partner

 

 

By:

/s/  GERALD A. SCHAASFMA      
Name: Gerald A. Schaasfma
Title: General Partner

 

 

Anthem Capital II, L.P.

By: Anthem Capital Partners, LLC, its general partner

 

 

By:

/s/  GERALD A. SCHAASFMA      
Name: Gerald A. Schaasfma
Title: General Partner

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

8



 

 

Johnson & Johnson Development Corporation

 

 

By:

/s/  TING PAU OEI      
Name: Ting Pau Oei
Title: Vice President

 

 

Cleveland Clinic Foundation

 

 

By:

/s/  DELOS M. COSGROVE      
Name: Delos M. Cosgrove, M.D.
Title: Chairman, Dept. Thoracic and Cardiovascular Surgery

 

 

EquityFourLife (Bahamas) Ltd.

 

 

By:

/s/  A. WEBER      
Name: A. Weber
Title: Director

 

 

By:

/s/  INELLIGIBLE      
Name: Inelligible
Title: Director

 

 

Johnston Associates Inc.

 

 

By:

/s/  ROBERT F. JOHNSTON      
Name: Robert F. Johnston
Title:

 

 

By:

/s/  ROBERT F. JOHNSTON      
Name: Robert F. Johnston

 

 

By:

/s/  ZOLA P. HOROVITZ      
Zola P. Horovitz, Ph.D.

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

9



 

 

Edward L. Erickson and Helen Masten-Erickson, as joint tenants by the entireties

 

 

By:

/s/  EDWARD L. ERICKSON      
Edward L. Erickson

 

 

By:

/s/  HELEN MASTEN-ERICKSON      
Helen Masten-Erickson

 

 

British Isles, LLC

 

 

By:

/s/  BARBARA MCNEIL JORDAN      
Name: Barbara McNeil Jordan
Title:

 

 

Heron I, LLC

 

 

By:

/s/  MARJORIE M. FINDLAY      
Name: Marjorie M. Findlay
Title:

 

 

Five Point, LLC

 

 

By:

/s/  ROBERT D. MCNEIL      
Name: Robert D. McNeil
Title:

 

 

Research and Diagnostic Systems, Inc.

 

 

By:

/s/  THOMAS E. OLAND      
Name: Thomas E. Oland
Title: President

 

 

/s/  DEEPAK KAMRA      
Deepak Kamra

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

10



 

 

 

/s/  STEPHEN M. BLOCH      
Stephen M. Bloch, M.D.

 

 

 

/s/  THOMAS M. MAWHINNEY      
Thomas M. Mawhinney

 

 

 

/s/  GREGORY KOPCHINSKY      
Gregory Kopchinsky

 

 

 

/s/  JOHN J. PACIFICO      
John J. Pacifico III

 

 

 

/s/  MATTHEW R. KRNA      
Matthew R. Krna

 

 

 

/s/  ERIC A. YOUNG      
Eric A. Young

 

 

 

/s/  ANDREW D. FIRLIK      
Andrew D. Firlik, M.D.

[COUNTERPART SIGNATURE PAGE TO
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT]

11




QuickLinks

    Exhibit 10.54
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT